Results 161 to 170 of about 5,502 (184)

Stepping into the Light: Defining Culprit Lesion in Non-ST Elevation Myocardial Infarction. [PDF]

J Saudi Heart Assoc
Pradana AD, Damarkusuma A, Hariawan H.
europepmc   +1 more source

An αIIbβ3 monoclonal antibody traps a semiextended conformation and allosterically inhibits large ligand binding. [PDF]

Blood Adv
Wang L, Wang J, Li J, Walz T, Coller BS.
europepmc   +1 more source

An αIIbβ3 ligand-mimetic murine monoclonal antibody that produces platelet activation by engaging the FcγIIa receptor. [PDF]

Blood Adv
Wang J, Buitrago L, Wang L, Li J, Walz T, Coller BS.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Delayed-onset eptifibatide-induced thrombocytopenia.

American Journal of Health-System Pharmacy, 2023
DISCLAIMER In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and ...
Travis R. Huffman, Evan Gleaves, Glee Lenoir, Rahil Rafeedheen   +3 more
semanticscholar   +1 more source

Safety and efficacy of eptifibatide in acute ischemic stroke requiring extracranial carotid artery stenting.

Interventional Neuroradiology, 2023
BACKGROUND The antiplatelet management in acute ischemic stroke requiring carotid artery stenting is heterogenous, with no clear guidelines to direct management.
M. Waters, J. Vargas, A. Turk, I. Chaudry, R. Turner   +4 more
semanticscholar   +1 more source

Complications and Management of Eptifibatide-Induced Thrombocytopenia

The Annals of Pharmacotherapy, 2021
Background Eptifibatide is used in acute coronary syndromes to reversibly block platelet aggregation by inhibiting the platelet glycoprotein IIb/IIIa receptor.
Faisal Masood, Saad Hashmi, A. Chaus, Anna Hertsberg, E. Ehrenpreis   +4 more
semanticscholar   +1 more source